Digital and computational pathology solutions provider Proscia on Tuesday announced the results of a retrospective study highlighting the potential of artificial intelligence (AI) to improve diagnostic accuracy for melanoma and other diseases with low pathologist concordance.
“Our technology relies on self-supervised learning to recognize incredibly subtle patterns, demonstrating the power of one of the most advanced approaches in AI,” Sean Grullon, lead AI scientist at Proscia and lead author of the study, said in a statement.